Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Akito Hata

Showing results (1-10 of 146) with videos related to

Pageof 15
Sort By:
Gan to Kagaku Ryoho. Cancer & Chemotherapy|August 23, 2023
[Non-Small Cell Lung Cancer]Ken Yamamoto, Akito Hata
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 3, 2015
Afatinib for Erlotinib Refractory Brain Metastases in a Patient with EGFR-Mutant Non-Small-Cell Lung Cancer: Can High-Affinity TKI Substitute for High-Dose TKI?Akito Hata, Nobuyuki Katakami
Annals of Vascular Diseases|April 17, 2024
Limb Salvage Surgery for Ponatinib-Induced Bilateral Chronic Limb-Threatening Ischemia in a Patient with Chronic Myeloid Leukemia with T315I Mutation in BCR-ABL: A Case ReportTakuo Nomura, Akito Hata
Gan to Kagaku Ryoho. Cancer & Chemotherapy|May 12, 2021
[How to Preserve QOL of Patients with Small Cell Lung Cancer-Cutting‒Edge Treatment of Brain and Bone Metastases]Taira Ninomaru, Akito Hata
Oncotarget|July 10, 2018
Maintenance ramucirumab monotherapy after intolerable toxicities following docetaxel plus ramucirumabAkito Hata, Nobuyuki Katakami
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 15, 2014
How sensitive are epidermal growth factor receptor-tyrosine kinase inhibitors for squamous cell carcinoma of the lung harboring EGFR gene-sensitive mutations?Akito Hata, Nobuyuki Katakami, Hiroshige Yoshioka
Journal of Gastrointestinal Cancer|June 2, 2014
Successful cetuximab therapy after failure of panitumumab rechallenge in a patient with metastatic colorectal cancer: restoration of drug sensitivity after anti-EGFR monoclonal antibody-free intervalAkito Hata, Nobuyuki Katakami, Naoto Kitajima
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 15, 2011
High-dose erlotinib for refractory brain metastases in a patient with relapsed non-small cell lung cancerAkito Hata, Reiko Kaji, Shiro Fujita, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 22, 2011
Does the addition of vascular endothelial growth factor inhibitors to epidermal growth factor receptor-tyrosine kinase inhibitor overcome T790M acquired resistance?Akito Hata, Reiko Kaji, Shiro Fujita, et al.
Internal Medicine (Tokyo, Japan)|August 19, 2014
Bevacizumab for critical brain metastases in a patient with pulmonary pleomorphic carcinomaAkito Hata, Shiro Fujita, Kenji Takayama, et al.
Pageof 15

Showing results (1-10 of 146) with videos related to

Sort By:
Pageof 15
Gan to Kagaku Ryoho. Cancer & Chemotherapy|August 23, 2023
[Non-Small Cell Lung Cancer]Ken Yamamoto, Akito Hata
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 3, 2015
Afatinib for Erlotinib Refractory Brain Metastases in a Patient with EGFR-Mutant Non-Small-Cell Lung Cancer: Can High-Affinity TKI Substitute for High-Dose TKI?Akito Hata, Nobuyuki Katakami
Annals of Vascular Diseases|April 17, 2024
Limb Salvage Surgery for Ponatinib-Induced Bilateral Chronic Limb-Threatening Ischemia in a Patient with Chronic Myeloid Leukemia with T315I Mutation in BCR-ABL: A Case ReportTakuo Nomura, Akito Hata
Gan to Kagaku Ryoho. Cancer & Chemotherapy|May 12, 2021
[How to Preserve QOL of Patients with Small Cell Lung Cancer-Cutting‒Edge Treatment of Brain and Bone Metastases]Taira Ninomaru, Akito Hata
Oncotarget|July 10, 2018
Maintenance ramucirumab monotherapy after intolerable toxicities following docetaxel plus ramucirumabAkito Hata, Nobuyuki Katakami
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 15, 2014
How sensitive are epidermal growth factor receptor-tyrosine kinase inhibitors for squamous cell carcinoma of the lung harboring EGFR gene-sensitive mutations?Akito Hata, Nobuyuki Katakami, Hiroshige Yoshioka
Journal of Gastrointestinal Cancer|June 2, 2014
Successful cetuximab therapy after failure of panitumumab rechallenge in a patient with metastatic colorectal cancer: restoration of drug sensitivity after anti-EGFR monoclonal antibody-free intervalAkito Hata, Nobuyuki Katakami, Naoto Kitajima
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 15, 2011
High-dose erlotinib for refractory brain metastases in a patient with relapsed non-small cell lung cancerAkito Hata, Reiko Kaji, Shiro Fujita, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 22, 2011
Does the addition of vascular endothelial growth factor inhibitors to epidermal growth factor receptor-tyrosine kinase inhibitor overcome T790M acquired resistance?Akito Hata, Reiko Kaji, Shiro Fujita, et al.
Internal Medicine (Tokyo, Japan)|August 19, 2014
Bevacizumab for critical brain metastases in a patient with pulmonary pleomorphic carcinomaAkito Hata, Shiro Fujita, Kenji Takayama, et al.
Pageof 15